SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287"
 

Search: onr:"swepub:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287" > Real-world cost-eff...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ohm, Lotta (author)

Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2014-10-21
  • Informa UK Limited,2015

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287
  • https://lup.lub.lu.se/record/7791118URI
  • https://doi.org/10.3109/10428194.2014.953141DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-239858URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:131560767URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • De två första författarna delar förstaförfattarskapet.
  • Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was (sic)52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to (sic)22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lundqvist, Adam (author)
  • Dickman, PaulKarolinska Institutet (author)
  • Höglund, MartinUppsala universitet,Hematologi(Swepub:uu)martinhl (author)
  • Persson, UlfLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)tft-upe (author)
  • Stenke, LeifKarolinska Institutet (author)
  • Carlsson, Katarina Steen (author)
  • Bjorkholm, MagnusKarolinska Institutet (author)
  • Karolinska InstitutetHematologi (creator_code:org_t)

Related titles

  • In:Leukemia & Lymphoma: Informa UK Limited56:5, s. 1385-13911042-81941029-2403

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view